Atyr PHARMA (NASDAQ:ATYR – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect Atyr PHARMA to post earnings of ($0.23) per share for the quarter. Persons interested in listening to the company’s earnings conference call can do so using this link.
Atyr PHARMA Stock Performance
Shares of ATYR stock opened at $3.15 on Thursday. The company has a market cap of $264.42 million, a price-to-earnings ratio of -3.35 and a beta of 1.10. The stock has a 50 day simple moving average of $3.69 and a 200-day simple moving average of $2.99. Atyr PHARMA has a 12-month low of $1.42 and a 12-month high of $4.66. The company has a current ratio of 5.41, a quick ratio of 5.41 and a debt-to-equity ratio of 0.02.
Wall Street Analyst Weigh In
A number of brokerages have recently issued reports on ATYR. HC Wainwright reissued a “buy” rating and set a $35.00 target price on shares of Atyr PHARMA in a research note on Tuesday, December 10th. Leerink Partners assumed coverage on Atyr PHARMA in a research note on Tuesday, February 18th. They issued an “outperform” rating and a $16.00 price objective for the company. Cantor Fitzgerald assumed coverage on Atyr PHARMA in a research note on Monday, January 6th. They issued an “overweight” rating for the company. Finally, Leerink Partnrs raised Atyr PHARMA to a “strong-buy” rating in a research note on Tuesday, February 18th. Six analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $18.60.
Atyr PHARMA Company Profile
aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.
Read More
- Five stocks we like better than Atyr PHARMA
- What Does a Stock Split Mean?
- Corporate Crawl: Where Business Trips Turn Into Party Nights
- How Technical Indicators Can Help You Find Oversold Stocks
- CrowdStrike’s Growth Remains Strong—Buy While It’s Down
- Stock Dividend Cuts Happen Are You Ready?
- Is Advanced Micro Devices Stock Slide Over?
Receive News & Ratings for Atyr PHARMA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atyr PHARMA and related companies with MarketBeat.com's FREE daily email newsletter.
-plc-logo-1200x675.jpg&h=45&w=95&zc=2){kind=logo}